illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. retail
  6. ›
  7. LBX Pharmacy
Company logo

LBX Pharmacy | Sustainability Performance

https://www.lbxdrugs.com/
Linkedin

Operates a chain of retail pharmacies and related healthcare services.

2001

China

10,001+ employees

Retail

$1B - 10B in revenue

$100M - 500M in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#6519
Overall
#144
in China
#242
in Retail

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

387 out of 451

Overview
Governance
TargetsESG scores and exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies

Company logo
Samson

China, Retail, Supermarkets

Company logo
Yonghui Superstores

China, Retail, Retail

Company logo
Zall Smart Commerce

China, Retail, Supermarkets

Market cap

69.4B $, 2026▼39.4% YoY

Revenue

3.1B $, 2025▼0.5% YoY

R&D intensity

0.23% 2025

Controversy level

Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
  • LBX Pharmacy Chain Joint Stock Company (Laobaixing), Chinese major retail pharmacy chain, has faced sustained Chinese NMPA enforcement scrutiny over alleged inadequate consumer protection compliance at multiple Chinese pharmacy customer operations, plus the contested 2024 sustained share price volatility amid Chinese consumer health market normalization affecting Chinese institutional shareholders.
Powered by illuminem

Market cap

69.4B $, 2026▼39.4% YoY

Revenue

3.1B $, FY2025▼0.5% YoY

EBITDA

124.3M $, FY2025▼9.1% YoY

Operating margin

4% Industry: 7▼21.8% YoY

Revenue & EBITDA

$3.1BFY2025 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends

Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

213.1M 2024▼38.8% YoY

Capex

71.1M 2024▼22.3% YoY

Debt/equity ratio

0.2 Industry: 1▼NaN% YoY

R&D intensity

0.2%FY2025

R&D as % of revenue

R&D as % of revenue
Industry benchmark

Powered by illuminem

Return on invested capital

5.0%FY2026
Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals

Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

3.1

▼ 4.9%

2023

3.1

▼ 1.9%

2024

3.1

▼ 1.8%

2025

35.1

2029

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Available

Human rights policy

Available

Recycling policy

Not available

Workplace health & safety policy

Available

16%
Independent Directors

3 out of 19 incl. management

Powered by illuminem

Overall score

79

Environment

76

Social

76

Governance

84

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Not available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

 Available
Not committed to key sustainability initiatives

Sustainability employees

    Available in
    Scale package

    Access
  • Email
  • Email